Literature DB >> 9431372

Impaired production of cytokines in a case of human leishmaniasis.

C Weinstock1, J Knobloch, W Schultheis, H Northoff.   

Abstract

A patient presented with the unique clinical picture of diffuse cutaneous and mucosal leishmaniasis caused by Leishmania tropica. Elevated serum levels of several cytokines including interleukin (IL) 2, interferon gamma (IFN-gamma), and tumor necrosis factor alpha were found. All cytokine levels returned to normal during therapy. No IL-10 or IL-4 levels were detectable. In whole blood cultures, induction of IFN-gamma by lipopolysaccharide (LPS) was completely negative, even after therapy. Concanavalin A (Con A)-induced release of IFN-gamma, like Con A-induced release of the other cytokines, was only initially impaired but returned to normal during therapy. Induction of the other cytokines by LPS was never impaired. The low expression of human leukocyte antigen DR on monocytes increased during IFN-gamma therapy but dropped when IFN-gamma treatment was ceased. We conclude that in this patient one or more of the routes of IFN-gamma production was impaired, thus resulting in insufficient IFN-gamma production in the infected lesions (although IFN-gamma was systemically present).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9431372     DOI: 10.1086/516123

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  2 in total

1.  A patient presenting with diffuse cutaneous leishmaniasis (DCL) as a first indicator of HIV infection in India.

Authors:  Kanika Khandelwal; Ram Awatar Bumb; Rajesh Dutt Mehta; Himanshu Kaushal; Claudio Lezama-Davila; Poonam Salotra; Abhay R Satoskar
Journal:  Am J Trop Med Hyg       Date:  2011-07       Impact factor: 2.345

2.  Three Leishmania/L. species--L. infantum, L. major, L. tropica--as causative agents of mucosal leishmaniasis in Iran.

Authors:  Sadegh Shirian; Ahmad Oryan; Gholam Reza Hatam; Yahya Daneshbod
Journal:  Pathog Glob Health       Date:  2013-07       Impact factor: 2.894

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.